opDNA: A Novel Synthetic DNA Starting Material for the Production of mRNA Therapies and Vaccines
This on-demand LSX: RNA Leaders webinar explores how synthetic, cell-free DNA is transforming mRNA manufacturing and why opDNA® offers a safer, more efficient alternative to plasmid DNA for IVT template production.
In the session, Heikki Lanckriet, CEO, explains how 4basebio has developed a proprietary, GMP-compliant, high-fidelity enzymatic DNA synthesis process for the production of linear DNA templates for mRNA therapies and vaccines.
The scalable 4basebio DNA production platform is sequence and template size independent, enabling rapid progression from sequence design to GMP-grade IVT templates in a matter of weeks.
What you’ll learn in this webinar
Why plasmid DNA is increasingly a bottleneck in mRNA manufacturing
How synthetic DNA improves safety, scalability, and regulatory readiness
The role of enzymatic DNA synthesis in IVT template production
Key considerations when transitioning from plasmid DNA to cell-free DNA
opDNA®: a next-generation DNA starting material for mRNA
opDNA® is a synthetic, linear DNA starting material designed specifically for in vitro transcription (IVT) processes used in mRNA manufacturing.
Key advantages include:
Elimination of endotoxins, host cell proteins, and bacterial contaminants, including antibiotic resistance genes
Improved DNA purity, yield, and performance in both in vitro and in vivo applications
No requirement for plasmid linearisation prior to IVT, reducing process complexity, timelines, and cost
Who should watch
mRNA process development and manufacturing teams
CMC, MSAT, and Regulatory Affairs professionals
Gene therapy and vaccine developers evaluating alternatives to plasmid DNA